Acne News

Researchers found that the efficacy of clascoterone cream 1% for the treatment of acne vulgaris increased over time up to 12 months and thus recommend persistent treatment regimens for optimal results, according to a study.

Transgender and gender-diverse individuals reported experiencing rejection and discrimination due to acne, as well as unique barriers to acne care, according to study results published in JAMA Dermatology.

The FDA’s approval of IDP-126 was the most read Healio acne story this year, followed by coverage of a study finding IDP-126 improves patients’ quality of life compared to vehicle. News regarding the efficacy of M-PDT and clascoterone cream, as well as an update to the FDA’s iPledge recommendations, rounded out 2023’s important acne updates.

A dermocosmetic containing salicylic acid may be used as an adjunct therapy to benzoyl peroxide to reduce the negative effects of prolonged benzoyl peroxide use, according to a study.

Isotretinoin is not associated with an increased risk for suicide or psychiatric conditions on a population level, according to a study.

The FDA has issued a notification to isotretinoin manufacturers to modify the iPledge Risk Evaluation and Mitigation Strategy to minimize procedural burdens on prescribers, pharmacists and patients.

Researchers found that early acne education may improve acne health literacy and encourage help-seeking behavior in adolescents, according to a study.

Higher acne vulgaris prevalence was associated with puberty status, skin of color and weight gain among adolescents, according to a study.

Doxycycline was associated with an earlier onset of acne-related hyperpigmentation during seasons with high sun exposure, whereas minocycline was not, according to a study.

Treatment with Janus kinase inhibitors may be associated with elevated odds of acne, especially among those with dermatologic conditions, according to a study.